Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Eileen Cheever

Physician Assistant, Medical Leominster, MA Physician Assistant

NPI 1205099785 CMS profile 10508131

100 Hospital Rd Ste 2D, Leominster, MA 01453

Open in the dashboard

General payments

$389,273

972 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eileen Cheever of Leominster, MA is reported in the CMS Open Payments database as having received $389,273 across 972 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $147,614 325
2024 General $110,059 301
2023 General $71,645 190
2022 General $32,625 88
2021 General $27,329 68

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eileen Cheever
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Eileen Cheever were reported at $147,614. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Eileen Cheever Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $27,329 $156 $41–$563 $132
2022 $32,625 $185 $55–$649 $149
2023 $71,645 $199 $58–$717 $160
2024 $110,059 $206 $62–$740 $164
2025 $147,614 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Lilly USA, LLC $98,101 230 payments
  2. Regeneron Healthcare Solutions, Inc. $58,683 183 payments
  3. Genzyme Corporation $52,729 86 payments
  4. AbbVie, Inc. $46,720 143 payments
  5. E.R. Squibb & Sons, L.L.C. $45,108 135 payments
  6. Janssen Biotech, Inc. $22,922 51 payments
  7. Dermavant Sciences, Inc. $20,514 36 payments
  8. Eli Lilly and Company $14,718 25 payments
  9. Organon LLC $10,403 17 payments
  10. Arcutis Biotherapeutics, Inc. $9,361 17 payments
  11. Other $10,013 49 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $252,236 239 payments
  2. Consulting Fee $67,303 59 payments
  3. Travel and Lodging $41,446 270 payments
  4. Food and Beverage $18,468 390 payments
  5. Honoraria $9,605 8 payments
  6. Education $214 6 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $53,426 87 payments
  2. EBGLYSS $52,816 119 payments
  3. SOTYKTU $33,831 103 payments
  4. TALTZ $32,948 78 payments
  5. DUPIXENT Immunology And Inflammation $30,937 101 payments
  6. VTAMA $26,192 50 payments
  7. DUPIXENT Inflammation And Immunology $24,195 76 payments
  8. TREMFYA $22,790 46 payments
  9. RINVOQ $16,961 67 payments
  10. SKYRIZI $16,141 46 payments
  11. Other $33,548 119 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

526

Median for Physician Assistant: 241

Drug cost

$1,350,567

Median for Physician Assistant: $4,110

Branded share of claims

39.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Pen Risankizumab-Rzaa Brand 37 $757,033
Dupixent Syringe Dupilumab Brand 51 $198,831
Tremfya Guselkumab Brand 12 $160,152
Enbrel Sureclick Etanercept Brand 17 $114,443
Otezla Apremilast Brand 20 $82,462
Vtama Tapinarof Brand 14 $19,765
Pimecrolimus Generic 14 $4,890
Betamethasone Diprop Augmented Betamethasone/Propylene Glyc Brand 55 $2,857
Tacrolimus Generic 19 $2,791
Metronidazole Generic 15 $1,825

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$72,616

Medicare's payments for the services billed

Medicare patients

759

Average age 73

Services billed

1,653

444 women, 315 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 40%
Ischemic heart disease 25%
Diabetes 22%
Chronic kidney disease 19%
Depression 19%
Cancer 15%
Atrial fibrillation 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SOTYKTU
$23,148 — —
DUPIXENT
$19,453 51 —
TREMFYA
$7,329 12 —
RINVOQ
$6,045 — —
SKYRIZI
$5,645 37 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

972 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record